Page last updated: 2024-09-02

tadalafil and Papillomavirus Infections

tadalafil has been researched along with Papillomavirus Infections in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Alnemri, A; Antysheva, Z; Argiris, A; Axelrod, R; Brown, B; Cognetti, DM; Curry, JM; Degryse, S; Gargano, S; Gibson, MK; Harshyne, LA; Johnson, JM; Kim, YJ; Kotlov, N; Kumar, G; Leiby, BE; Linnenbach, AJ; Luginbuhl, AJ; Mahoney, MG; Mannion, K; Martinez-Outschoorn, U; Netterville, J; Rodeck, U; Shimada, A; Shukla, SK; South, AP; Tuluc, M; Zinner, R	1

Trials

1 trial(s) available for tadalafil and Papillomavirus Infections

Article	Year
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5 Topics: Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Nivolumab; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Tadalafil; Treatment Outcome; Tumor Microenvironment	2022

Article

Year

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5

Topics: Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Nivolumab; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Tadalafil; Treatment Outcome; Tumor Microenvironment

2022